Casey Woodring
JPMorgan Chase & Co, Research Division
All right. Great. Thank you, everybody, for joining us today. My name is Casey Woodring from the Life Science Tools and Diagnostics team here at JPMorgan. Pleased to be joined by the management team of Repligen. We’ll do the corporate presentation first, and then leave time for Q&A. So with that, Olivier, over to you.
Olivier Loeillot
President, CEO & Director
Thank you so much, Casey. Thanks for coming, and looking forward to telling you a bit more about Repligen. The usual safe harbor statement. So for those of you who are not completely familiar with the company, we are headquartered in Waltham, Massachusetts.
We are really a pure bioprocessing play, about 2,000 employees in total. And for the vast majority of our portfolio, we’ve got dual manufacturing in U.S. and in Europe. And finally, at the midpoint of our guidance in 2025, we were at USD 733 million in sales.
What’s our vision? We want to be the global innovation, and you will hear me mentioning innovation several times today, leader in bioprocessing with a very extensive portfolio of very differentiated data-driven solutions across most therapeutical modalities.
So there are a couple of takeaways, and I’m going to start with that so that you remember them right at the beginning. The first one again is innovation. So we’ve been really playing on that side for the last 10 years, and we are playing in a pretty large bioprocessing market, as you know, and we play against very big competitors.
